



AVVISO DI SEMINARIO

Il giorno 07/05/2026 alle ore 14:30

Nell'Aula Seminari del Dipartimento di Scienze
e Tecnologie Chimiche

Dott.ssa Rita De Santis

CEO/CSO

Kiran Biotech S.r.l.

Terrà un seminario dal titolo:

**THE WINDING ROAD OF KIRAN BIOTECH
TO MAKE POSSIBLE THE IMPOSSIBLE**

Proponente: Prof. Daniel Oscar Cicero

Abstract:

Kiran Biotech is an innovative startup founded in 2024 by two senior industrial scientists. Kiran owns the IP rights to AvidinOX, a very peculiar delivery platform that has already been tested in patients in one of its multiple and diverse possible declinations. Specifically, the platform has been used to deliver radionuclides to inoperable tumor lesions (17 patients showed very good tolerability and high-quality dosimetry data).

There is a rationale for delivering cancer therapeutics selectively to avoid/minimize systemic side effects. The platform could be used for restricted delivery of checkpoint inhibitors, potentially optimizing their current use, which is associated with significant systemic tolerability issues.

It is proposed to further clinically validate the platform:

- 1- Site-restricted delivery of radionuclides can be further improved by using an alternative radiolabeled ligand (AI-assisted design)
- 2- Topical lung delivery by aerosol of anti-cancer therapeutics, i.e., proprietary anti-PDL1 antibody, could be advanced from pre-clinical (existing published and unpublished data) to clinical PoC

All above, seeking academic collaborations to generate new patent applications and papers.